Jefferies Financial Group’s Dianthus Therapeutics DNTH Stock Holding History

Jefferies Financial Group’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$574K	Sell	5,886 -196,524	-97%	-$17.2M	﹤0.01%	1211
2026 Q1	$17M	Buy	+202,410	New	+$11.7M	0.12%	146
2024 Q2	–	Sell	-7,600	Closed	-$228K	–	1518
2024 Q1	$228K	Sell	7,600 -5,600	-42%	-$122K	﹤0.01%	1304
2023 Q4	$137K	Hold	13,200	–	–	﹤0.01%	1515
2023 Q3	$180K	Buy	+13,200	New	+$166K	﹤0.01%	1364

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Jefferies Financial Group's DNTH Position: Q2 2026 in Review

Jefferies Financial Group reduced its Dianthus Therapeutics (DNTH) stake by 97% in Q2 2026, selling an estimated $17.2M and leaving 5,886 shares worth $574K. The position accounts for ﹤0.01% of the portfolio, ranked #1211.

Jefferies Financial Group first reported a position in DNTH in Q3 2023 and has held it in 5 quarters since. The position peaked at $17M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Jefferies Financial Group held 5,886 shares of Dianthus Therapeutics worth $574K as of Q2 2026.
Jefferies Financial Group sold 196,524 Dianthus Therapeutics shares in Q2 2026, an estimated $17.2M.
Dianthus Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #1211 holding.
Jefferies Financial Group first reported a position in Dianthus Therapeutics in Q3 2023 and has held it in 5 quarters since.
Jefferies Financial Group's Dianthus Therapeutics position peaked at $17M in Q1 2026.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.